Viridian Therapeutics(VRDN)
$29.96-1.48 (-4.71%)
VRDN
Viridian Therapeutics ownership
$29.96
At close:-1.48 (-4.71%)
Want to see VRDN full AI Analyst Report?
Viridian Therapeutics (VRDN) Ownership - Who Owns Viridian Therapeutics?
1,573 Followers
Viridian Therapeutics (VRDN) Ownership Overview
- 4.57% Insiders
- 27.89% Mutual Funds
- 13.43% Other Institutional Investors
- 15.56% ETFs
- 38.56% Public Companies and Individual Investors
The ownership structure of Viridian Therapeutics (VRDN) stock is a mix of institutional, retail, and individual investors. Approximately 56.88% of the company’s stock is owned by Institutional Investors, 4.57% is owned by Insiders, and 38.56% is owned by Public Companies and Individual Investors.
Institutional holdings as of
The ownership structure of Viridian Therapeutics (VRDN) stock is a mix of institutional, retail, and individual investors. Approximately 56.88% of the company’s stock is owned by Institutional Investors, 4.57% is owned by Insiders, and 38.56% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 19, 2026 | Jennifer Tousignant | $348,194 | |
| May 12, 2026 | Fairmount Funds Management Llc | $19,999,990 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2026 | Perceptive Advisors Llc | $7,854,097 | |
| Sep 30, 2026 | Antipodes Partners Ltd | $13,775 | |
| Sep 30, 2026 | $192,087,199 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 9,329,150 | Institution | 8.22% | 279,501,334 |
| Fairmount Funds Management Llc | 5,090,928 | Insider | 4.48% | 152,524,203 |
| Peter Harwin | 5,090,928 | Institution | 4.48% | 152,524,203 |
| Vanguard | 4,881,373 | Institution | 4.30% | 146,245,935 |
| Vanguard Index Funds | 4,467,394 | Institution | 3.93% | 133,843,124 |
| Ishares | 4,455,639 | Institution | 3.92% | 133,490,944 |
| Fidelity Securities Fund | 3,136,580 | Institution | 2.76% | 93,971,937 |
| Spdr | 2,937,682 | Institution | 2.59% | 88,012,953 |
| Fidelity Select Portfolios | 2,808,304 | Institution | 2.47% | 84,136,788 |
| Fidelity Advisor Series Vii | 2,542,464 | Institution | 2.24% | 76,172,221 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 4,467,394 | Institution | 3.93% | 133,843,124 |
| Fidelity Securities Fund | 3,136,580 | Institution | 2.76% | 93,971,937 |
| Fidelity Select Portfolios | 2,808,304 | Institution | 2.47% | 84,136,788 |
| Fidelity Advisor Series Vii | 2,542,464 | Institution | 2.24% | 76,172,221 |
| Fidelity Concord Street Trust | 2,062,635 | Institution | 1.82% | 61,796,545 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,447,742 | Institution | 1.27% | 43,374,350 |
| Fidelity Rutland Square Trust Ii | 1,404,701 | Institution | 1.24% | 42,084,842 |
| T. Rowe Price New Horizons Fund, Inc. | 1,351,696 | Institution | 1.19% | 40,496,812 |
| Fidelity Salem Street Trust | 1,123,744 | Institution | 0.99% | 33,667,370 |
| Fidelity Capital Trust | 1,089,196 | Institution | 0.96% | 32,632,312 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Total Stock Market ETF, VTI ETF | 2,659,076 | Institution | 2.34% | 65,599,405 |
| iShares Russell 2000 ETF, IWM ETF | 2,617,328 | Institution | 2.30% | 82,288,792 |
| SPDR S&P BIOTECH ETF, XBI ETF | 2,572,261 | Institution | 2.27% | 77,476,501 |
| Vanguard Extended Market ETF, VXF ETF | 1,292,571 | Institution | 1.14% | 31,887,727 |
| iShares Russell 2000 Value ETF, IWN ETF | 847,090 | Institution | 0.75% | 26,632,510 |
| Dimensional U.S. Small Cap ETF, DFAS ETF | 683,038 | Institution | 0.60% | 20,573,105 |
| Schwab U.S. Small-Cap ETF, SCHA ETF | 604,739 | Institution | 0.53% | 18,214,739 |
| Vanguard Russell 2000 ETF, VTWO ETF | 590,538 | Institution | 0.52% | 14,568,572 |
| iShares Micro-Cap ETF, IWC ETF | 307,488 | Institution | 0.27% | 9,667,423 |
| U.S. Micro Cap Portfolio ETF, DFMC ETF | 285,532 | Institution | 0.25% | 6,612,921 |
FAQ
Who Owns Viridian Therapeutics (VRDN)?
According to the latest TipRanks data (13F holdings as of September 30, 2026), approximately 56.88% of the company's stock is held by institutional investors, 4.57% is held by insiders, and 38.56% is held by public companies and individual investors.
What percentage of Viridian Therapeutics (VRDN) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of September 30, 2026), approximately 56.88% of Viridian Therapeutics (VRDN) stock is held by institutional investors: 27.89% by mutual funds, 15.56% by ETFs and 13.43% by other institutional investors.
What percentage of Viridian Therapeutics (VRDN) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of September 30, 2026), approximately 38.56% of Viridian Therapeutics (VRDN) stock is held by public companies and individual investors.
Who owns the most shares of Viridian Therapeutics (VRDN)?
BlackRock, Inc. owns the most shares of Viridian Therapeutics (VRDN).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

